Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches

BMC Complementary and Alternative Medicine

Volumn 15, Issue 1, 2015, Pages

  Yang, Zhenzhong ^a   Wang, Linli ^a   Zhang, Feng ^a   Li, Zheng ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

3T3 L1 cells; KKAy mice; Network pharmacology; TCM; Type 2 diabetes mellitus; Xiao Ke An

Indexed keywords

CHINESE DRUG; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HERBACEOUS AGENT;

3T3 CELL LINE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL DIFFERENTIATION; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; IN VITRO STUDY; INHIBITION KINETICS; INSULIN RESISTANCE; LIPID STORAGE; LIVER WEIGHT; MALE; MICROARRAY ANALYSIS; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN WEIGHT; UPREGULATION; WEIGHT CHANGE; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MOUSE;

3T3-L1 CELLS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; INSULIN RESISTANCE; LIPID METABOLISM; MICE;

EID: 84938902249     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-015-0785-2     Document Type: Article

References (25)

1. Holman RR. Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. Nat Rev Endocrinol. 2013;9(2):67-8.
2. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182-97.
3. Gu J, Zhang H, Chen L, Xu S, Yuan G, Xu X. Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus. Comput Biol Chem. 2011;35(5):293-7.
4. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-72.
5. Mopuri R, Ganjayi M, Banavathy KS, Parim BN, Meriga B. Evaluation of anti-obesity activities of ethanolic extract of Terminalia paniculata bark on high fat diet-induced obese rats. BMC Complement Altern Med. 2015;15(1):76.
6. Azushima K, Tamura K, Wakui H, Maeda A, Ohsawa M, Uneda K, et al. Bofu-Tsu-Shosan, an oriental herbal medicine, exerts a combinatorial favorable metabolic modulation including antihypertensive effect on a mouse model of human metabolic disorders with visceral obesity. PloS One. 2013;8(10):e75560.
7. Etxeberria U, de la Garza AL, Campión J, Martínez JA, Milagro FI. Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase. Expert Opin Ther Targets. 2012;16(3):269-97.
8. Qi L-W, Liu E-H, Chu C, Peng Y-B, Cai H-X, Li P. Anti-diabetic agents from natural products-an update from 2004 to 2009. Curr Top Med Chem. 2010;10(4):434-57.
9. Yang Z, Wang Y, Wang Y, Zhang Y. Bioassay-guided screening and isolation of aα-glucosidase and tyrosinase inhibitors from leaves of Morus alba. Food Chem. 2012;131(2):617-25.
10. Oh M-R, Park S-H, Kim S-Y, Back H-I, Kim M-G, Jeon J-Y, et al. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2014;14.
11. Dong M, Gong ZC, Dai XP, Lei GH, Lu HB, Fan L, et al. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2. Clin Exp Pharmacol Physiol. 2011;38(12):824-9.
12. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114(6):950-6.
13. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.
14. Nan Z, Nan H, He Z, Nan J, Liu D. Treatment type 2 diabetes with Xiao-Ke-An, 920 cases of clinical study and experimental animal research. Academic Periodical of Changchun College of Traditional Chinese Medicine. 2005;21(1):13-5.
15. Wang L, Li Z, Zhao X, Liu W, Liu Y, Yang J, et al. A network study of Chinese medicine Xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway. Evid base Compl Alternative Med. 2013;2013.
16. Yang Z, Liu W, Zhang F, Li Z, Cheng Y. Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach. Acta Pharmacol Sin. 2015;36(6):699-707.
17. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2012;136(1):451-72.
18. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87(6):2764-9.
19. Fang H, Harris SC, Su Z, Chen M, Qian F, Shi L, Perkins R, Tong W: ArrayTrack: an FDA and public genomic tool. In: Protein Networks and Pathway Analysis. edn. Edited by Yuri N, Julie B: Springer; 2009: 379-398.
20. Wu L, Wang Y, Nie J, Fan X, Cheng Y. A network pharmacology approach to evaluating the efficacy of Chinese medicine using genome-wide transcriptional expression data. Evid Based Complement Alternat Med. 2013;2013.
21. Yang Z, Yang J, Liu W, Wu L, Xing L, Wang Y, et al. T2D@ ZJU: a knowledgebase integrating heterogeneous connections associated with type 2 diabetes mellitus. Database. 2013;2013:bat052.
22. Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia a randomized controlled trial. J Cardiovasc Pharmacol Ther. 2014;19(3):296-303.
23. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431-2.
24. Li P, Qi L-W, Liu E-H, Zhou J-L, Wen X-D. Analysis of Chinese herbal medicines with holistic approaches and integrated evaluation models. TrAC Trends in Analytical Chemistry. 2008;27(1):66-77.
25. Jiang W-Y. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci. 2005;26(11):558-63.